Abstract:Backgrounds and purposes Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin's lymphoma. The prognosis of PCNSL is poor and heterogeneous. MicroRNA is associated with prognosis of various cancers. Our study is the first time to compare circulating microRNAs of PCNSL patients with different prognosis using miRNA microarray scanning and find novel microRNAs associated with prognosis of PCNSL by further large-scale validation. Materials and methods From a retrospective cohort, we collected the clinical data of patients who were diagnosed as PCNSL in Huashan Hospital between January 2007 and June 2016. We collected clinical data and blood samples from residual blood routine test of PCNSLs. First, we compared circulating microRNAs between patients with different overall survival (OS) using miRNA microarray scanning. Second, PCR assay was used for miRNAs quantification in blood sample from 6 patients that had long overall survival and other 6 patients that had short overall survival. Further miRNA validation was made by PCR assay in blood sample from 94 patients to validate prognostic value of miRNAs in PCNSLs. The Kruskal-Wallis and Mann-Whitney U tests were used for quantitative parameters and the χ2 square test was used for non-quantitative parameters. Univariate analysis was performed using log-rank test, and survival distributions were analyzed by the Kaplan-Meier curve and log-rank test. Multivariate analysis was done by Cox regression model. Results A total of 90 differentially expressed miRNAs were identified, including 24 up-regulated miRNAs and 66 down-regulated miRNAs using miRNA microarray scanning. Then PCR assay was used for 10 differentially expressed miRNAs quantification in blood sample from 6 patients that had long overall survival and 6 patients that had short overall survival. Mir-21, mir-129-5p, mir-144-5, mir-363-5p, mir-409-3p, mir-1246, mir-1299 and mir-1825 showed no differences between 2 groups, while the expression of mir-455-3P and mir-940 between 2 groups are significantly different (P<0.05). Further validation in 94 patients showed median OS in miR-940 overexpression group was 91 months and in miR-940 low-expression group was 28 months (P=0.0005), while median PFS in miR-940 overexpression group was 25 months and in miR-940 low-expression group was 16 months (P =0.0292). Multivariate analysis of COX model showed miR-940 was independent factors for OS and PFS. Conclusion Circulating mir-940 had prognostic value in PCNSL and was an independent prognostic factor for PCNSL. Figure 1 Disclosures No relevant conflicts of interest to declare.

Prognostic Value of Microrna-10B Overexpression in Peripheral Blood Mononuclear Cells of Nonsmall-Cell Lung Cancer Patients

MiR-362-5p As a Novel Prognostic Predictor of Cytogenetically Normal Acute Myeloid Leukemia

Microrna Profiling and Prediction of Recurrence/Relapse-Free Survival in Stage I Lung Cancer

Expression of microRNA-150 in Peripheral Blood and Its Clinical Significance in Patients with Non-Small Cell Lung Cancer

Altered Mir-143 and Mir-150 Expressions in Peripheral Blood Mononuclear Cells for Diagnosis of Non-Small Cell Lung Cancer.

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Analysis of Genetic Variants and the Cerna Network of Mir-9 in Non-Small Cell Lung Cancer

Expression of Micrornas-106B in Nonsmall Cell Lung Cancer

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer

A Serum Microrna Signature As a Prognostic Factor for Patients with Advanced NSCLC and Its Association with Tissue Microrna Expression Profiles.

Downregulation of Serum Mir-101 is Associated with Worse Prognosis in Non-Small Cell Lung Cancer.

Prognostic Implications of Decreased Microrna-101-3p Expression in Patients with Non-Small Cell Lung Cancer

Circulating Micrornas is a Potential Prognostic Biomarker in Primary Central Nervous System Lymphoma

Down-regulation of Microrna-144-3p and Its Clinical Value in Non-Small Cell Lung Cancer: a Comprehensive Analysis Based on Microarray, Mirna-Sequencing, and Quantitative Real-Time PCR Data

MicroRNA-155 Expression Has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.

Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.

Up-Regulation Of Microrna-93 Predicates Advanced Clinicopathological Features And Serves As An Unfavorable Risk Factor For Survival Of Patients With Non-Small Cell Lung Cancer

Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer